IN
INCPF.US InnoCare Pharma Limited
- Market cap
- USD 2.83B
- P/E
- 20.0x
- P/B
- 2.30x
- ROE
- 10.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INCPF.US undervalued?
Graham numberINCPF.US trades 43.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InnoCare Pharma Limited fundamental analysis
No fundamental analysis for InnoCare Pharma Limited yet.
InnoCare Pharma Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InnoCare Pharma Limited
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous sys…
Full company profileInnoCare Pharma Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InnoCare Pharma Limited annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 102K | 1.62M | 1.25M | 1.36M | 1.04B | 625M | 739M | 1.01B | 2.30B | 2.79B |
| Gross Profit | 102K | 1.62M | -32.5M | 1.36M | 977M | 482M | 610M | 871M | 2.01B | 2.51B |
| Operating Income | -340M | -554M | -2.15B | -559M | -181M | -770M | -651M | -526M | 441M | 696M |
| EBITDA | -336M | -547M | -2.14B | -548M | -149M | -808M | -517M | -313M | 556M | 696M |
| Net Income | -342M | -550M | -2.14B | -391M | -64.5M | -887M | -631M | -441M | 626M | 872M |
| EPS | -0.27 | -0.44 | -1.71 | -0.40 | -0.04 | -0.60 | -0.37 | -0.26 | 0.36 | 0.49 |
| Balance Sheet | ||||||||||
| Total Assets | 107M | 2.20B | 2.62B | 4.54B | 7.40B | 10.3B | 9.92B | 9.41B | 10.8B | 11.5B |
| Total Liabilities | 499M | 3.04B | 5.56B | 1.38B | 1.74B | 2.68B | 2.74B | 2.66B | 2.79B | 3.27B |
| Shareholders' Equity | -392M | -904M | -3.00B | 3.10B | 5.60B | 7.60B | 7.15B | 6.73B | 7.73B | 8.19B |
| Cash & Short-term Investments | 46.9M | 2.05B | 2.37B | 3.97B | 6.25B | 9.01B | 8.22B | 7.29B | 7.34B | 6.49B |
| Total Debt | 136M | 1.03B | 1.14B | 1.17B | 1.27B | 1.25B | 1.35B | 1.27B | 1.61B | 2.13B |
| Cash Flow | ||||||||||
| Operating Cash Flow | -49.4M | -17.7M | -79.8M | -173M | 167M | -566M | -671M | -366M | 199M | 381M |
| Capital Expenditure | 1.42M | 20.1M | 45.5M | 251M | 167M | 370M | 255M | 78.2M | 68.3M | 135M |
| Free Cash Flow | -50.8M | -37.8M | -125M | -424M | -11.0K | -936M | -926M | -444M | 131M | 246M |
| Ratios | ||||||||||
| ROE | - | - | - | -12.6% | -1.2% | -11.7% | -8.8% | -6.6% | 8.1% | 10.6% |
| ROA | -318.2% | -25.0% | -81.9% | -8.6% | -0.9% | -8.6% | -6.4% | -4.7% | 5.8% | 7.6% |
| Net Profit Margin | -335,033.3% | -34,010.5% | -171,723.2% | -28,694.6% | -6.2% | -141.8% | -85.5% | -43.7% | 27.2% | 31.3% |
| Debt to Equity | - | - | - | 0.38x | 0.23x | 0.16x | 0.19x | 0.19x | 0.21x | 0.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
InnoCare Pharma Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 363M | 0.21 | - |
| 2023 | CNY 1.15M | 0.00 | - |
| 2022 | USD 3.26M | 0.00 | - |
| 2021 | USD 3.26M | 0.00 | - |
| 2020 | USD 3.26M | 0.00 | - |
| 2019 | USD 3.26M | 0.00 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns InnoCare Pharma Limited
- Insiders 19.86%
- Institutions 41.67%
- Public & others 38.47%
- Shares outstanding 1.49B
- Free float 1.03B
InnoCare Pharma Limited company profile
- Company name
- InnoCare Pharma Limited
- Ticker
- INCPF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,388
- Fiscal year end
- December
- Address
- Building 8, Beijing, China, 102206
- Phone
- 86 10 6660 9999
- Website
- innocarepharma.com
About InnoCare Pharma Limited
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
InnoCare Pharma Limited management
10- Dr. Jisong Cui Ph.D.Co-Founder, Chairwoman & CEO · born 1963
- Dr. Renbin Zhao Ph.D.Senior VP of Clinical Development & Medical Research and Executive Director · born 1969
- Mr. Xin FuChief Financial Officer · born 1978
- Mr. Nan GaoChief Operating Officer · born 1974
- Yue TanAccounting Supervisor
- Dr. Xiangyang Chen Ph.D.Chief Technology Officer · born 1967
- Ms. Bei YuanJoint Company Secretary & Senior Director of Investor elations
- Ms. Junsu WangGeneral Counsel · born 1977
- Mr. Davy Ouyang Ph.D.VP & Head of Biology
- Mr. Jeff ChenChief Commercial Officer